Profile data is unavailable for this security.
About the company
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.
- Revenue in USD (TTM)0.00
- Net income in USD-44.02m
- Incorporated2018
- Employees56.00
- LocationPulse Biosciences Inc3957 Point Eden WayHAYWARD 94545-3720United StatesUSA
- Phone+1 (510) 906-4600
- Fax+1 (302) 655-5049
- Websitehttps://www.pulsebiosciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Standard Biotools Inc | 136.30m | -164.66m | 746.02m | 534.00 | -- | 1.46 | -- | 5.47 | -0.9018 | -0.9018 | 0.6606 | 1.37 | 0.2561 | 2.25 | 5.73 | 255,243.50 | -22.29 | -28.17 | -26.55 | -33.60 | 46.67 | 51.58 | -87.05 | -74.85 | 3.53 | -- | 0.0974 | -- | 8.57 | -1.20 | 60.73 | -- | 50.06 | -- |
| Alphatec Holdings Inc | 540.28m | -180.91m | 846.97m | 839.00 | -- | 50.40 | -- | 1.57 | -1.34 | -1.34 | 4.00 | 0.2847 | 0.7736 | 1.13 | 7.30 | 643,959.50 | -25.90 | -30.97 | -33.24 | -39.47 | 69.44 | 66.02 | -33.48 | -46.22 | 1.21 | -4.59 | 0.9273 | -- | 37.45 | 39.38 | -23.36 | -- | 67.92 | -- |
| Castle Biosciences Inc | 287.59m | -3.10m | 872.88m | 610.00 | -- | 2.06 | 87.40 | 3.04 | -0.1346 | -0.1346 | 10.45 | 15.30 | 0.6302 | 7.38 | 7.44 | 471,457.40 | -0.6791 | -9.43 | -0.7383 | -10.17 | 81.86 | 80.58 | -1.08 | -28.46 | 7.92 | -- | 0.0238 | -- | 60.38 | 57.35 | 14.41 | -- | 117.94 | -- |
| Embecta Corp | 1.12bn | 69.70m | 900.73m | 2.20k | 12.94 | -- | 8.32 | 0.805 | 1.21 | 1.21 | 19.36 | -13.24 | 0.8882 | 2.11 | 11.60 | 508,590.90 | 5.53 | -- | 7.91 | -- | 66.42 | -- | 6.23 | -- | 1.61 | 2.06 | 1.88 | -- | -0.7703 | -- | -68.52 | -- | -- | -- |
| Bioventus Inc | 536.89m | -41.96m | 959.54m | 1.03k | -- | 6.36 | -- | 1.79 | -0.6595 | -0.6595 | 8.48 | 1.86 | 0.6591 | 1.95 | 4.18 | 553,495.90 | -6.70 | -5.52 | -9.65 | -7.27 | 66.53 | 68.25 | -10.16 | -10.94 | 0.956 | 1.08 | 0.6697 | -- | 0.0445 | 9.93 | 6.91 | -- | 23.51 | -- |
| Figs Inc | 550.80m | 18.68m | 965.36m | 354.00 | 54.92 | 2.40 | 43.27 | 1.75 | 0.1029 | 0.1029 | 3.04 | 2.35 | 1.18 | 1.23 | 58.02 | 1,555,932.00 | 3.99 | -- | 4.65 | -- | 68.02 | -- | 3.39 | -- | 3.89 | -- | 0.00 | -- | 7.87 | -- | 6.85 | -- | -- | -- |
| Artivion Inc | 376.97m | -8.32m | 1.06bn | 1.50k | -- | 3.57 | 70.36 | 2.80 | -0.2076 | -0.2076 | 9.11 | 7.06 | 0.481 | 1.67 | 5.44 | 251,316.00 | -1.07 | -2.20 | -1.15 | -2.36 | 64.63 | 65.51 | -2.22 | -5.34 | 4.04 | 1.07 | 0.5177 | -- | 12.82 | 6.14 | -60.09 | -- | 5.13 | -- |
| Pulse Biosciences Inc | 0.00 | -44.02m | 1.10bn | 56.00 | -- | 36.59 | -- | -- | -0.7916 | -0.7916 | 0.00 | 0.4883 | 0.00 | -- | -- | 0.00 | -76.43 | -93.21 | -84.97 | -104.99 | -- | -- | -- | -12,332.25 | -- | -- | 0.00 | -- | -100.00 | -- | 27.85 | -- | -15.20 | -- |
| Avanos Medical Inc | 682.40m | 7.00m | 1.11bn | 3.77k | 157.53 | 0.907 | 21.25 | 1.63 | 0.1532 | 0.1671 | 14.71 | 26.62 | 0.4105 | 1.93 | 5.20 | 180,960.00 | 0.4211 | -0.6527 | 0.4737 | -0.7338 | 55.82 | 54.45 | 1.03 | -1.60 | 1.49 | 7.06 | 0.1253 | -- | -1.58 | 0.6357 | -146.05 | -- | -18.37 | -- |
| Establishment Labs Holdings Inc | 151.35m | -83.20m | 1.19bn | 857.00 | -- | 26.35 | -- | 7.84 | -3.11 | -3.11 | 5.62 | 1.61 | 0.5307 | 0.8525 | 2.72 | 166,685.00 | -29.17 | -33.22 | -34.29 | -41.12 | 66.04 | 64.73 | -54.97 | -43.19 | 2.91 | -20.68 | 0.8114 | -- | 2.13 | 21.96 | -4.38 | -- | 69.16 | -- |
| BioLife Solutions Inc | 121.17m | -53.87m | 1.19bn | 409.00 | -- | 3.70 | -- | 9.81 | -1.21 | -1.64 | 2.69 | 6.97 | 0.2999 | 1.99 | 5.39 | 296,254.30 | -13.33 | -13.76 | -14.60 | -15.04 | 41.27 | 36.76 | -44.46 | -42.99 | 1.81 | -5.98 | 0.0651 | -- | -11.43 | 48.65 | 52.49 | -- | 86.35 | -- |
| Owens & Minor, Inc. | 10.53bn | -42.44m | 1.22bn | 13.70k | -- | 1.42 | 5.10 | 0.1163 | -0.5532 | -0.5532 | 137.98 | 11.17 | 1.99 | 6.95 | 15.78 | 768,728.30 | -0.8014 | 1.32 | -1.25 | 2.07 | 20.78 | 16.48 | -0.403 | 0.5614 | 0.5141 | 2.11 | 0.7076 | 0.798 | 3.80 | 1.87 | -284.47 | -- | 25.91 | -- |
| Inmode Ltd | 416.63m | 149.20m | 1.33bn | 581.00 | 10.05 | 1.92 | 8.87 | 3.19 | 1.73 | 1.73 | 4.84 | 9.09 | 0.5228 | 1.62 | 11.78 | 717,084.30 | 18.72 | 31.32 | 20.79 | 35.64 | 82.27 | 84.46 | 35.81 | 39.65 | 8.09 | -- | 0.00 | 0.00 | 8.32 | 37.49 | 22.54 | 54.65 | 13.10 | -- |
| Integra Lifesciences Holdings Corp | 1.57bn | 23.65m | 1.35bn | 3.95k | 58.76 | 0.8799 | 8.85 | 0.8617 | 0.2961 | 0.2961 | 20.02 | 19.77 | 0.399 | 1.55 | 5.81 | 396,986.10 | 0.6023 | 3.33 | 0.6618 | 3.68 | 61.54 | 63.67 | 1.51 | 7.99 | 2.10 | 5.88 | 0.5433 | 0.00 | -1.03 | 0.9219 | -62.48 | 2.19 | -2.97 | -- |
| AtriCure Inc | 429.95m | -40.12m | 1.41bn | 1.20k | -- | 3.06 | -- | 3.29 | -0.8606 | -0.8606 | 9.22 | 9.49 | 0.7217 | 1.68 | 8.27 | 358,294.20 | -6.73 | -3.72 | -7.58 | -4.10 | 74.84 | 74.36 | -9.33 | -7.64 | 2.93 | -11.79 | 0.12 | -- | 20.84 | 14.64 | 34.49 | -- | 46.56 | -- |
Data as of Sep 20 2024. Currency figures normalised to Pulse Biosciences Inc's reporting currency: US Dollar USD
7.14%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 956.33k | 1.73% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 827.67k | 1.50% |
| Bank of America, NA (Private Banking)as of 31 Mar 2024 | 777.13k | 1.41% |
| Geode Capital Management LLCas of 30 Jun 2024 | 423.97k | 0.77% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 349.74k | 0.63% |
| Griffin Asset Management, Inc.as of 30 Jun 2024 | 257.68k | 0.47% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 187.14k | 0.34% |
| Westside Investment Management LLCas of 30 Jun 2024 | 63.60k | 0.12% |
| Citadel Securities LLCas of 31 Mar 2024 | 54.08k | 0.10% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 45.40k | 0.08% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
